Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CandMig III study
2019-003386-18Phase 2Completed
- Sponsor
- St. Olavs University Hospital
- Start
- Oct 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of candesartan in migraine, migraine with aura and migraine without aura (2 arms), sponsored by St. Olavs University Hospital. Primary endpoint: Number of migraine days per 4 weeks. Started Oct 2019; status: completed.
02
Drugs
candesartan
03
Conditions
migrainemigraine with auramigraine without aura
Beyond the preview
Go deeper on 2019-003386-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003386-18.